Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial

Creative Commons License

Halvorsen S., Atar D., Yang H., De Caterina R., EROL Ç., Garcia D., ...Daha Fazla

EUROPEAN HEART JOURNAL, cilt.35, sa.28, ss.1864-1872, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 28
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1093/eurheartj/ehu046
  • Dergi Adı: EUROPEAN HEART JOURNAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1864-1872
  • Anahtar Kelimeler: Atrial fibrillation, Age, Anticoagulants, Stroke, Bleeding, Apixaban, THROMBOEMBOLIC EVENTS, ORAL ANTICOAGULANTS, RISK, THERAPY, PREVALENCE, REDUCTION
  • Ankara Üniversitesi Adresli: Evet

Özet

Aims The risk of stroke in patients with atrial fibrillation (AF) increases with age. In the ARISTOTLE trial, apixaban when compared with warfarin reduced the rate of stroke, death, and bleeding. We evaluated these outcomes in relation to patient age.